Efficiency and Safety of Nasal Positive Airway Pressure Systems During Endoscopy (Endo-Breath)
Hypercapnia, Hypoxia
About this trial
This is an interventional prevention trial for Hypercapnia
Eligibility Criteria
Inclusion Criteria: ASA III (poorly controlled Diabetes Melitus (DM) or arterial hypertension (HTN), Chronic obstructive Pulmonary Disease (COPD), morbid obesity (BMI≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, End Stage Renal Disease (ESRD), Advanced Liver Disease ( ACLD) ; history (>3 months) of Myocardial Infarction, coronary artery disease (CAD) , transient ischemic attack (TIA), or CAD/stents) ASA IV (recent (<3 months MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, sepsis, ARD or ESRD not undergoing regularly scheduled dialysis Active Malignancy (ECOG Performance >2) Exclusion Criteria: Patients with tracheotomy Pregnancy Intubation assisted endoscopy Procedure without sedation
Sites / Locations
- Universitätsklinikum Ulm
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention Group
Control Group
Patients undergoing endoscopic procedures receiving oxygen supplementation through nasal positive airway pressure system ( 10 litters/minute).
Patients undergoing endoscopic procedures receiving conventional oxygen supplementation through nasal cannula (6 litters/minute).